JAK-IN-18
JAK-IN-18 is a potent inhibitor of JAK. JAK-IN-18 is useful for the research of multiple diseases, particularly ocular, skin, and respiratory diseases (extracted from patent WO2018204238A1, compound 1) [1].
Product Specifications
CAS Number
2247925-32-0
UNSPSC
12352005
Target
JAK
Type
Reference compound
Related Pathways
Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/jak-in-18.html
Solubility
10 mM in DMSO
Smiles
FC1=CC(C2=CC(F)=C(O)C=C2CC)=CC3=C1C(C(N4)=NC5=C4CN(C(CN6CCOCC6)=O)CC5)=NN3
Molecular Formula
C27H28F2N6O3
Molecular Weight
522.55
References & Citations
[1]Paul R. Fatheree, et al. Fused imidazo-piperidine jak inhibitor compound. Patent WO2018204238A1.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
BNC400411-100 1x 100 µL
BCL-10 (BL10/411), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 
BNC401531-100 1x 100 µL
IL3RA / CD123 (Acute Myeloid Leukemia Marker) (IL3RA/1531), CF640R conjugate, 0.1mg/mL
Sign In for Pricing
View Details 